Localized In Vivo Prodrug Activation Using Radionuclides
Journal of Nuclear Medicine · 2025
DOI: 10.2967/jnumed.124.268559 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Nuclear Medicine, 2025. Verfasst von Jeremy M Quintana und 17 weiteren Autor:innen. Beteiligte Einrichtung: Center for Systems Biology, Massachusetts General Hospital, Boston, Massachusetts. Hauptthemen laut MEDLINE: Prodrugs, Radioisotopes. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, NCI NIH HHS, NIBIB NIH HHS.
Abstract (Originalsprache)
Radionuclides used for imaging and therapy can show high molecular specificity in the body with appropriate targeting ligands. We hypothesized that local energy delivered by molecularly targeted radionuclides could chemically activate prodrugs at disease sites while avoiding activation in off-target sites of toxicity. As proof of principle, we tested whether this strategy of radionuclide-induced drug engagement for release (RAiDER) could locally deliver combined radiation and chemotherapy to maximize tumor cytotoxicity while minimizing off-target exposure to activated chemotherapy.
Methods
We screened the ability of radionuclides to chemically activate a model radiation-activated prodrug consisting of the microtubule-destabilizing monomethyl auristatin E (MMAE) caged by a radiation-responsive phenyl azide, and we interpreted experimental results using the radiobiology computational simulation suite TOPAS-nBio. RAiDER was evaluated in syngeneic mouse models of cancer using the fibroblast activation protein inhibitor (FAPI) agents [99mTc]Tc-FAPI-34 and [177Lu]Lu-FAPI-04 and the prostate-specific membrane antigen (PSMA) agent [177Lu]Lu-PSMA-617, combined with caged MMAE or caged exatecan. Biodistribution in mice, combined with clinical dosimetry, estimated the relationship between radiopharmaceutical uptake in patients and anticipated concentrations of activated prodrug using RAiDER.
Results
RAiDER efficiency varied by 70-fold across radionuclides (99mTc > 111In > 177Lu > 64Cu > 32P > 68Ga > 223Ra > 18F), yielding up to 320 nM prodrug activation/Gy of exposure from 99mTc. Computational simulations implicated low-energy electron-mediated free radical formation as driving prodrug activation. Radionuclide-activated caged MMAE restored the prodrug's ability to destabilize microtubules and increased its cytotoxicity by up to 2,600-fold that of the nonactivated prodrug. Mice treated with [99mTc]Tc-FAPI-34 and caged MMAE accumulated concentrations of activated MMAE that were up to 3,000 times greater in tumors than in other tissues. RAiDER with [99mTc]Tc-FAPI-34 or [177Lu]Lu-FAPI-04 delayed tumor growth, whereas monotherapies did not (P < 0.003). Clinically guided dosimetry suggests sufficient radiation doses can be delivered to activate therapeutically meaningful levels of prodrug.
Conclusion
This proof-of-concept study shows that RAiDER is compatible with multiple radionuclides commonly used in nuclear medicine and can potentially improve the efficacy of radiopharmaceutical therapies to treat cancer safely. RAiDER thus shows promise as an effective strategy to treat disseminated malignancies and broadens the capability of radiopharmaceuticals to trigger diverse biologic and therapeutic responses.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Systems Biology, Massachusetts General Hospital, Boston, Massachusetts.
- Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
- Department of Imaging, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
- Office of Radiation Safety, Massachusetts General Hospital, Boston, Massachusetts.
- Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
- Institute for Innovation in Imaging, Massachusetts General Hospital, Boston, Massachusetts; and.
Förderung
- NIGMS NIH HHS
- NCI NIH HHS
- NIBIB NIH HHS
- NIDDK NIH HHS
- NIH HHS
Zitieren
APA
Quintana, J. M., Jiang, F., Kang, M., Valladolid Onecha, V., Könik, A., Qin, L., Rodriguez, V. E., Hu, H., Borges, N., Khurana, I., Banla, L. I., Le Fur, M., Caravan, P., Schuemann, J., Bertolet, A., Weissleder, R., Miller, M. A., & Ng, T. S. C. (2025). Localized In Vivo Prodrug Activation Using Radionuclides. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.124.268559
Vancouver
Quintana JM, Jiang F, Kang M, Valladolid Onecha V, Könik A, Qin L, et al. Localized In Vivo Prodrug Activation Using Radionuclides. Journal of Nuclear Medicine. 2025. doi:10.2967/jnumed.124.268559
BibTeX
@article{Quintana2025,
author = {Quintana, Jeremy M and Jiang, Fangchao and Kang, Mikyung and Valladolid Onecha, Victor and Könik, Arda and Qin, Lei and Rodriguez, Victoria E and Hu, Huiyu and Borges, Nicholas and Khurana, Ishaan and Banla, Leou I and Le Fur, Mariane and Caravan, Peter and Schuemann, Jan and Bertolet, Alejandro and Weissleder, Ralph and Miller, Miles A and Ng, Thomas S C},
title = {Localized In Vivo Prodrug Activation Using Radionuclides},
journal = {Journal of Nuclear Medicine},
year = {2025},
doi = {10.2967/jnumed.124.268559}
}
EUVIMED